Variability in Liver Biopsy Assessment: Data from the Pegozafermin Phase 1b/2a Study in Subjects with Non-Alcoholic Steatohepatitis (NASH)

November 08, 2022

Study Background

The objective of the study was to assess the impact on histological endpoints in the Phase 1b/2a POC study of assessment by 4 individual expert NASH pathologists. Loomba et al.

Get In Touch

PathAI Media

Company Contact

Liz Storti

Chief People Officer

elizabeth.storti@pathai.com

Media Contact

Daniel Donato

LifeSci Communications

ddonato@lifescicomms.com

516-474-0554